A Double-Blind Trial of Long-Term Lithium Therapy in Mental Defectives

1974 ◽  
Vol 124 (578) ◽  
pp. 52-57 ◽  
Author(s):  
Graham J. Naylor ◽  
J. M. Donald ◽  
David Le Poidevin ◽  
Andrew H. Reid
Keyword(s):  
Therapeutic Effect ◽  
Affective Disorders ◽  
Lithium Therapy ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
Mental Defectives

The therapeutic effect of lithium in mania was first described by Cade (1949), but the possibility that lithium could have a prophylactic action in recurrent affective disorders was not suggested until some years later (Hartigan, 1963; Baastrup, 1964). The early studies of the prophylactic action of lithium were open trials, in which both investigator and patient knew that the patient was receiving the drug. More recently, controlled double-blind studies have confirmed these early reports (Melia, 1970; Coppenet al., 1971; Cundallet al., 19712).

A Double-Blind Trial of Long-Term Lithium Therapy in Mental Defectives

1974 ◽  
Vol 124 (1) ◽  
pp. 52-57 ◽  
Author(s):  
G. J. NAYLOR ◽  
J. M. DONALD ◽  
D. LE POIDEVIN ◽  
A. H. REID
Keyword(s):  
Lithium Therapy ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
Mental Defectives

A Pilot Study for a Prospective, Randomized, Double-Blind Trial of the Influence of Anesthetic Depth on Long-Term Outcome

2014 ◽  
Vol 58 (5) ◽  
pp. 237-238
Author(s):  
Timothy G. Short ◽  
Kate Leslie ◽  
Douglas Campbell ◽  
Matthew T. V. Chan ◽  
Tomas Corcoran ◽  
...  
Keyword(s):  
Pilot Study ◽  
Double Blind Trial ◽  
Double Blind ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Anesthetic Depth ◽  
Blind Trial

Normalization By Suloctidil Of Decreased Platelet Survival In Patients With Heart Prosthetic Valves In Randomized Controlled Double Blind Trial

1981 ◽  
Author(s):  
N Ciavarella ◽  
S Antoneecchit ◽  
N D’Elia ◽  
P Ranieri ◽  
A Manzini
Keyword(s):  
Double Blind Trial ◽  
Anticoagulant Treatment ◽  
Double Blind ◽  
Blind Trial ◽  
Randomized Controlled ◽  
Prosthetic Valves ◽  
Platelet Survival

Platelets play an important role in thromboembo lie episodes in the life of patients with heart prosthetic valves. Decreased platelet survival and increased B-Tromboglobulin and Platelet F4 in the blood are constant features of such condition.45 patients on long term anticoagulant treatment (thrombotest 5-10%),26 males(mean age 46) and 19 females(mean age 44), were studied. 22 normal sub jects served as controls.Platelets survival was studied with MDA production after 5oo mg Aspirin intake and was found signifi canly reduced in patients in comparison to contro Is(p.8.00±1.4 days;c.10.00±1.67 days; P<0.01).BTG and PF4 as measured by RIA were increased (BTG:p.97.8±59 NG/ML;c.29.18±22.40 NG/ML; P<0.01) (PF4:p.36.6±26.5 NG/ML;c.6.29±4.78 NG/ML; P<0.01) The patients were randomly allocated to one of the following groups( 15 subjects each): placebo, Suloctidil 600 mg:die, Suloctidil 1200 mg:die. Duration treatment was 30 days.The effect of Suloctidil was significantly different from that of placebo( P<0.005),as regards Platelet survival without difference between dosa ges of the drug;as concerns BTG and PF4 the chang es under placebo and drug were not different.

A Pilot Study for a Prospective, Randomized, Double-Blind Trial of the Influence of Anesthetic Depth on Long-Term Outcome

2014 ◽  
Vol 118 (5) ◽  
pp. 981-986 ◽  
Author(s):  
Timothy G. Short ◽  
Kate Leslie ◽  
Douglas Campbell ◽  
Matthew T. V. Chan ◽  
Tomas Corcoran ◽  
...  
Keyword(s):  
Pilot Study ◽  
Double Blind Trial ◽  
Double Blind ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Anesthetic Depth ◽  
Blind Trial

Athrombogenic coating of long-term venous catheter for cancer patients: a prospective, randomised, double-blind trial

2011 ◽  
Vol 91 (4) ◽  
pp. 613-620 ◽  
Author(s):  
Felicitas Hitz ◽  
Dirk Klingbiel ◽  
Aurelius Omlin ◽  
Salomé Riniker ◽  
Andreas Zerz ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Venous Catheter ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial

scholarly journals Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial

2013 ◽  
Vol 16 (10) ◽  
pp. 2219-2234 ◽  
Author(s):  
Emmanuelle Corruble ◽  
Christian de Bodinat ◽  
Carole Belaïdi ◽  
Guy M. Goodwin
Keyword(s):  
Tolerability Profile ◽  
Double Blind Trial ◽  
Emotional Experiences ◽  
Double Blind ◽  
Global Satisfaction ◽  
Sleep Complaints ◽  
Subjective Sleep ◽  
Blind Trial ◽  
Randomized Controlled

Abstract In the present randomized, controlled, double-blind trial (12 wk treatment plus double-blind extension for 12 wk), 25–50 mg/d agomelatine (n = 164) and 10–20 mg/d escitalopram (n = 160) were compared for short- and long-term efficacy, subjective sleep and tolerability. The effects of these drugs on emotional experiences were also compared in patients having completed the Oxford Questionnaire on the Emotional Side-Effects of Antidepressants (agomelatine: n = 25; escitalopram: n = 20). Agomelatine and escitalopram similarly improved depressive symptoms, with clinically relevant score changes over 12 and 24 wk and notable percentage of remitters (week 12: 60.9 and 54.4%; week 24: 69.6 and 63.1% respectively). Over the 12 and 24-wk treatment periods, the ‘global satisfaction on sleep’ scores increased in both treatment groups and did not differ between groups. Satisfaction with sleep–wake quality was high in both groups; the ‘wellness feeling on waking’ was more improved with agomelatine than with escitalopram (p = 0.02). In patients with pronounced sleep complaints, quality of sleep and feeling on waking were significantly more improved with agomelatine than with escitalopram (p = 0.016 and p = 0.009, respectively). Emotional blunting was less frequent on agomelatine than on escitalopram. Indeed, 28% of patients on agomelatine vs. 60% on escitalopram felt that their emotions lacked intensity and 16% of patients on agomelatine vs. 53% on escitalopram felt that things that they cared about before illness did not seem important any more (p = 0.024). The tolerability profile of agomelatine was found to be superior to that of escitalopram and the incidence of patients with at least one emergent adverse event leading to treatment discontinuation was lower in the agomelatine group than in the escitalopram group (5.5 vs. 10.6%). The findings suggest that agomelatine displays additional long-term clinical benefits on sleep–wake quality and emotional experiences over escitalopram in the management of depression.

Sign in / Sign up

Export Citation Format

Share Document